Therapeutic and prophylactic strategies in renal failure

被引:0
作者
Brandenburg, VM [1 ]
Heintz, B [1 ]
Floege, J [1 ]
机构
[1] Rhein Westfal TH Aachen, Univ Klinikum, Med Klin 2, D-52057 Aachen, Germany
来源
INTERNIST | 2003年 / 44卷 / 07期
关键词
arterial hypertension; diabetes mellitus; supportive therapy; renal failure;
D O I
10.1007/s00108-003-0948-y
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The number of patients with end-stage renal disease is constantly growing. If patients at risk are identified early enough, currently available therapeutic options allow a potent primary and secondary prevention of progressive renal failure. If the underlying disease can not be eliminated, the mainstay of the therapy are supportive measures such as antihypertensive and, in case of an underlying diabetes mellitus, antidiabetic therapy, dietary restrictions as well as avoidance of additional nephrotoxic agents. Furthermore, even a mild renal insufficiency has been identified as a potent cardiovascular risk factor. The second major goal of supportive therapy therefore is a reduction of the markedly increased cardiovascular morbidity of these patients. This can be achieved through treatment of various consequences of renal failure, such as hyperparathyroidism, renal anemia etc. Supportive therapy thus represents a highly complex and interdisciplinary treatment, which should prompt an early inclusion of a nephrologist into the therapeutic strategy.
引用
收藏
页码:819 / +
页数:10
相关论文
共 108 条
[1]   Development and progression of nephropathy in type 2 diabetes: The United Kingdom Prospective Diabetes Study (UKPDS 64) [J].
Adler, AI ;
Stevens, RJ ;
Manley, SE ;
Bilous, RW ;
Cull, CA ;
Holman, RR .
KIDNEY INTERNATIONAL, 2003, 63 (01) :225-232
[2]   Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study [J].
Adler, AI ;
Stratton, IM ;
Neil, HAW ;
Yudkin, JS ;
Matthews, DR ;
Cull, CA ;
Wright, AD ;
Turner, RC ;
Holman, RR .
BMJ-BRITISH MEDICAL JOURNAL, 2000, 321 (7258) :412-419
[3]   Renal failure associated with the use of celecoxib and rofecoxib [J].
Ahmad, SR ;
Kortepeter, C ;
Brinker, A ;
Chen, M ;
Beitz, J .
DRUG SAFETY, 2002, 25 (07) :537-544
[4]   Nephrotoxic effects in high-risk patients undergoing angiography. [J].
Aspelin, P ;
Aubry, P ;
Fransson, S ;
Strasser, R ;
Willenbrock, R ;
Berg, KJ .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (06) :491-499
[5]  
Bakris George L, 2002, J Clin Hypertens (Greenwich), V4, P420
[6]   ACE inhibition or angiotensin receptor blockade: Impact on potassium in renal failure [J].
Bakris, GL ;
Siomos, M ;
Richardson, D ;
Janssen, I ;
Bolton, WK ;
Hebert, L ;
Agarwal, R ;
Catanzaro, D .
KIDNEY INTERNATIONAL, 2000, 58 (05) :2084-2092
[7]   The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin [J].
Besarab, A ;
Bolton, WK ;
Browne, JK ;
Egrie, JC ;
Nissenson, AR ;
Okamoto, DM ;
Schwab, SJ ;
Goodkin, DA .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (09) :584-590
[8]   Hyperhomocysteinaemia, folate and vitamin B12 in unsupplemented haemodialysis patients: effect of oral therapy with folic acid and vitamin B12 [J].
Billion, S ;
Tribout, B ;
Cadet, E ;
Queinnec, C ;
Rochette, J ;
Wheatley, P ;
Bataille, P .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2002, 17 (03) :455-461
[9]   Prevalence and socio-economic aspects of chronic kidney disease [J].
Bommer, J .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2002, 17 :8-12
[10]   Predictive performance of renal function equations for patients with chronic kidney disease and normal serum creatinine levels [J].
Bostom, AG ;
Kronenberg, F ;
Ritz, E .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2002, 13 (08) :2140-2144